Actively Recruiting
Open-Label Study of Iloperidone Oral Tablets for 1 Year in Adolescents With Schizophrenia or Bipolar I Disorder
Led by Vanda Pharmaceuticals · Updated on 2026-10-01
100
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of iloperidone, an oral tablet drug, in adolescents aged 12 to 17 years diagnosed with schizophrenia or bipolar I disorder. This study is a phase 4, open-label trial that aims to observe how well patients tolerate iloperidone over a treatment period lasting up to 52 weeks. Participants receive iloperidone in doses ranging from 8 to 24 mg per day throughout the one-year treatment. This is a single-group study without a placebo or comparison group, where all enrolled patients receive the study drug openly. The study focuses on monitoring the occurrence of treatment-emergent adverse events during this period. During the study, participants will be regularly assessed for safety, including monitoring for any adverse events that arise while taking the medication. The main measurement is the number of participants experiencing such events throughout the treatment year. The study is sponsored by Vanda Pharmaceuticals and will continue until the end of 2028, involving adolescents who provide assent along with parental consent.
CONDITIONS
Brief Title
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Research Team
V
Vanda Pharmaceuticals Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here